Atreca (BCEL) Competitors

Atreca (NASDAQ:BCEL) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Which has more volatility & risk, BCEL or CANF?

Atreca has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.

Which has preferable earnings and valuation, BCEL or CANF?

Can-Fite BioPharma has higher revenue and earnings than Atreca. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atreca	N/A	N/A	-$97.16M	-$2.50	-0.09
Can-Fite BioPharma	$785K	9.74	-$10.17M	-$2.59	-0.83

Is BCEL or CANF more profitable?

Atreca has a net margin of 0.00% compared to Can-Fite BioPharma's net margin of -1,146.62%. Can-Fite BioPharma's return on equity of -143.59% beat Atreca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atreca	N/A	-157.90%	-71.39%
Can-Fite BioPharma	-1,146.62%	-143.59%	-83.78%

Do analysts rate BCEL or CANF?

Atreca presently has a consensus target price of $10.75, suggesting a potential upside of 4,764.25%. Can-Fite BioPharma has a consensus target price of $15.00, suggesting a potential upside of 594.44%. Given Atreca's higher probable upside, equities analysts plainly believe Atreca is more favorable than Can-Fite BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atreca	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the MarketBeat Community believe in BCEL or CANF?

Atreca received 94 more outperform votes than Can-Fite BioPharma when rated by MarketBeat users. Likewise, 67.86% of users gave Atreca an outperform vote while only 4.35% of users gave Can-Fite BioPharma an outperform vote.

Company	Underperform	Outperform
Atreca	Outperform Votes 95 67.86%	Underperform Votes 45 32.14%
Can-Fite BioPharma	Outperform Votes 1 4.35%	Underperform Votes 22 95.65%

Do institutionals & insiders have more ownership in BCEL or CANF?

34.9% of Atreca shares are held by institutional investors. Comparatively, 1.5% of Can-Fite BioPharma shares are held by institutional investors. 11.3% of Atreca shares are held by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Does the media favor BCEL or CANF?

In the previous week, Can-Fite BioPharma had 3 more articles in the media than Atreca. MarketBeat recorded 3 mentions for Can-Fite BioPharma and 0 mentions for Atreca. Can-Fite BioPharma's average media sentiment score of 0.52 beat Atreca's score of 0.45 indicating that Can-Fite BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Atreca	Neutral
Can-Fite BioPharma	Positive

Summary

Atreca beats Can-Fite BioPharma on 9 of the 16 factors compared between the two stocks.